Targeted immunotherapy for non-small cell lung cancer

Table 1 Ongoing clinical trials of programmed death-1 antibodies in non-small cell lung cancer

Therapy	Trial	Study population	Study design	Ref.
Nivolumab phase I safety study	NCT01454102 (checkmate 012)	Advanced NSCLC	Nivolumab as single agent vs combination with various chemotherapies	[55]
Nivolumab phase III study to determine OS	NCT01673867 (checkmate 057)	Previously treated (failed platinum based) advanced NSCLC	Nivolumab compared to docetaxel in previously treated patients	[56]
Nivolumab phase III study to look for tumor size and OS	NCT01642004 (checkmate 017)	Previously treated (failed platinum based) advanced NSCLC	Nivolumab compared to docetaxel in previously treated patients	[57]
Nivolumab phase III study assessing tumor size after treatment	NCT01721759 (checkmate 063)	Previously treated and failed 2 lines of chemotherapy	Assess response rate objectively (monitoring tumor size) in patients receiving Nivolumab	[58]
Nivolumab phase II study to determine Response	NCT01928576	Previously treated, advanced/recurrent NSCLC	Assess objective response with Nivolumab, preceded by epigenetic therapy (azacitadine IV or oral, entinostat) priming	[59]
MK-3475 (lambrolizumab) phase Idose limiting study followed by part B to assess safety and tolerability	NCT01928576	Any solid tumor, or advanced NSCLC	Patients with any solid tumor will receive lambrolizumab to assess dose; followed by part B where patients with advanced NSCLC will receive this therapy in combination with chemotherapy	[60]

Table 2 Ongoing clinical trials of programmed death ligand 1 mAbs in non-small cell lung cancer

Therapy	Trial	Study population	Study design	Ref.
MPDL3280A	NCT01846416	Advanced NSCLC, tumor positive for PD-L1 on IHC	Assess safety, efficacy and objective response rates in patients with PD-L1 positive NSCLC	[64]
MPDL3280A	NCT01903993	Advanced NSCLC, failed platinum based chemo	MPDL-3280A vs Docetaxel after failure of platinum based therapy in patients with advanced NSCLC	[65]

NSCLC: Non-small cell lung cancer; PD-L1: Programmed death ligand 1; IHC: Immunohistochemistry.